Results 61 to 70 of about 13,568,693 (193)

N,N-Dimethyltryptamine

, 2020
A mystery that has been going on for centuries. The N,N-dimethyltryptamine (DMT) molecule, which is found in every living thing, especially in humans at the time of birth and death, and which some claim to open the door of the parallel universes, is a ...
YÜCEL, Kamile
core   +1 more source

5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study

Frontiers in Psychiatry, 2023
Psychedelic therapy is, arguably, the next frontier in psychiatry. It offers a radical alternative to longstanding, mainstays of treatment, while exciting a paradigm shift in translational science and drug discovery.
Anya Ragnhildstveit, Anya Ragnhildstveit, Ryan Khan, Paul Seli, Paul Seli, Lisa Claire Bass, Lisa Claire Bass, River Jude August, River Jude August, Miriam Kaiyo, Miriam Kaiyo, Nathaniel Barr, Laura Kate Jackson, Michael Santo Gaffrey, Michael Santo Gaffrey, Michael Santo Gaffrey, Joseph Peter Barsuglia, Lynnette Astrid Averill, Lynnette Astrid Averill, Lynnette Astrid Averill   +19 more
doaj   +1 more source

Trends in new psychoactive substance poisonings in the Netherlands: A 14‐year retrospective analysis (2012–2025)

Addiction, Volume 121, Issue 10, Page 2822-2832, October 2026.
Abstract Background and aims Data on the presence of new psychoactive substances (NPS) mainly originate from drug‐checking, law enforcement and wastewater analysis sources, while data on NPS poisonings are scarce. In Europe, the documented incidence rate of NPS poisonings is highest in the Netherlands.
Johanna J. Nugteren‐van Lonkhuyzen, Irma S. van den Hengel‐Koot, Claudine C. Hunault, Dylan W. de Lange, Antoinette J. H. P. van Riel, Laura Hondebrink   +5 more
wiley   +1 more source

Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review

Journal of Clinical Psychology, Volume 82, Issue 9, Page 1263-1270, September 2026.
ABSTRACT Recent studies have shown promising results for psychedelics in the treatment of psychiatric disorders. Both in clinical and recreational settings, contextual elements, such as music, can influence the experience of users and may be linked to positive outcomes.
Lucas Cruz, Fernando R. Beserra, Julia M. K. Freind, Sandro E. Rodrigues, Daniel C. Mograbi   +4 more
wiley   +1 more source

Development of Japanese Versions of the 4‐Item Mystical Experience Questionnaire and 7‐Item Challenging Experience Questionnaire

Neuropsychopharmacology Reports, Volume 46, Issue 3, September 2026.
The authorized Japanese versions of the MEQ‐4 and CEQ‐7 were developed in accordance with ISPOR good practice guidelines. These brief scales enable the rapid assessment of mystical and challenging experiences among Japanese speakers. ABSTRACT Introduction Interest in therapeutic applications of psychedelics has recently resurged.
Futaba Umemura, Hiroko Kotajima‐Murakami, Justin C. Strickland, Albert Garcia‐Romeu, Matthew W. Johnson, Kazutaka Ikeda   +5 more
wiley   +1 more source

Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation

Future Pharmacology
Background/Objectives: In this study, we present an analysis of ayahuasca, a psychedelic preparation containing N,N-dimethyltryptamine (DMT) and β-carbolines, such as harmine (HRM), a reversible monoamine oxidase A (MAO-A) inhibitor that enables the oral
Gabriella de Souza Gomes Ribeiro, Pieter Annaert, Frederico Severino Martins, Tania Marcourakis   +3 more
doaj   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 345-356, August 2026.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT)

European Journal of Pharmaceutical Sciences
There is considerable evidence from the literature that psychedelics, such as N,N-dimethyltryptamine (DMT), are safe and effective treatments for depression. However, clinical administration to induce psychedelic effects and expensive psychotherapy-assisted treatments likely limit accessibility to the average patient.
Christopher G. Witowski, Mika R. Hess, Nate T. Jones, Molly C. Pellitteri Hahn, John Razidlo, Riya Bhavsar, Christina Beer, Natalie Gonzalez-Velazquez, Cameron O. Scarlett, Cody J. Wenthur, Jacqueline L. von Salm   +10 more
openaire   +2 more sources

Does N,N-dimethyltryptamine (DMT) adequately explain near-death experiences? [PDF]

Journal of Near-Death Studies, 2012
Abstract: Some NDE researchers have suggested that because some users of psychedelic drugs have experiences purportedly similar to near-death experiences (NDEs), neural receptors and neurotransmitters affected by a particular drug may underlie out-of-body experiences and NDEs. One of the most recent psychedelic candidates that allegedly causes NDE-like
openaire   +2 more sources

Phenomenology of N,N-Dimethyltryptamine Use: A Thematic Analysis

, 2022
N,N-dimethyltryptamine (DMT) is an endogenous hallucinogenic compound in the same chemical class as the more common psilocybin and the neurotransmitter serotonin.
Rock, Adam J, Cott, Christopher
core